Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $8 from $4 and keeps an Outperform rating on the shares. The firm notes the company reported earnings, confirmed Crohn’s disease as its lead indication, and reiterated guidance for SL-325 results in Q2 2026. Wedbush looks for low ADA rates in the healthy volunteer data as initial proof of differentiation from TL1A directed competitors in addition to other markers like receptor occupancy as mechanistic evidence supporting development.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs transferred with Buy rating at Needham
- Buy Rating on SL-325: Differentiated DR3 Targeting in IBD Supports Attractive Risk/Reward and $14 Price Target
- Shattuck Labs reports Q4 EPS (12c), consensus (13c)
- Shattuck Labs expects available cash to fund operations into 2029
- Shattuck Labs Sets Earlier Date for 2026 Annual Meeting